Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced Wednesday that it expects its partner Sarepta Therapeutics (NASDAQ:SRPT), ...

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three ...

Sarepta’s new clinical programs from Arrowhead aim to treat facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, idiopathic pulmonary fibrosis and spinocerebellar ataxia 2.

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases.